Company profile
Avalo Therapeutics, Inc.
Pipeline1 asset
- AbdakibartAVTX-009 / IL-1β / Humanized IgG4 monoclonal antibody / Immune-mediated inflammatory diseasesHidradenitis suppurativaPhase 2 completed; registrational Phase 3 plannedPositive topline Phase 2 LOTUS results reported May 5, 2026
Latest news16 items
All newsAvalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
Presentation / Abstract • Phase 2EADV poster presentation Wed, Sep 30, 2026, 7:00 AM CEST
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Trial Results • Phase 2Topline results Tue, May 5, 2026